Main Content

Pseudomyogenic Haemangioendothelioma

Pseudomyogenic haemangioendothelioma is a rarely metastasizing endothelial neoplasm that occurs more frequently in young adult males. It often presents as multiple discontiguous nodules in different tissue planes and histologically mimics a myoid tumor or epithelioid sarcoma.

Symptoms & Causes

Introduction

Pseudomyogenic haemangioendothelioma is an endothelial tumor in young males, mimicking myoid tumors or epithelioid sarcoma, often presenting as multiple nodules.

Reference
WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2020 [cited 2024 09 11]. (WHO classification of tumours series, 5th ed.; vol. 3). Available from: https://tumourclassification.iarc.who.int/chapters/33.

Related Terminology
Not recommended: epithelioid sarcoma–like haemangioendothelioma.

Subtype(s)
None

Symptoms

About half of affected patients present with painless and half with painful nodules. In approximately 60% of patients, this disease is multifocal, often involving multiple tissue planes. Most patients (75%) present with cutaneous and subcutaneous nodules. About 50% of affected patients have intramuscular lesions, and 20% of patients have lytic bone lesions. Some patients have intraosseous lesions without soft tissue involvement. By PET, the tumors in most patients are highly avid for FDG; this technique can be used to visualize clinically occult deep lesions in patients who present with cutaneous nodules.

Localization

Pseudomyogenic haemangioendothelioma usually arises on the lower limbs (55% of cases); the upper limbs and trunk are less commonly affected (20% each); tumors rarely occur on the head or neck (5%).

Epidemiology

Pseudomyogenic haemangioendothelioma is rare. There is a marked male predominance (M:F ratio: 3.5:1), with peak incidence in young adults (mean age: 30 years). Only 20% of patients are aged > 40 years at presentation.

Etiology

Unknown

Diagnosis & Treatment

Staging

Not clinically relevant

Pathogenesis

Pseudomyogenic haemangioendothelioma was initially described as being caused by a balanced translocation t(7;19)(q22;q13), resulting in the fusion of SERPINE1 to FOSB. Recently, an alternative ACTB-FOSB gene fusion was identified in half of the cases. These fusions lead to upregulation of FOSB, probably by a promoter-swapping mechanism, because most of the FOSB gene is retained in the fusion (fused at exon 2). SERPINE1 (fusion occurs in non-coding exon 1) is normally highly expressed in vascular cells, and ACTB (fused at exon 3) is a ubiquitously expressed gene. FOSB is a member of the FOS family of transcription factors, which encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1, regulating cell proliferation, differentiation, angiogenesis, and survival. Upregulation of FOSB causes activation of the AP-1 complex. Overexpression of the retained part of FOSB in endothelial cells affects angiogenesis in vitro, with the retained part acting as an active transcription factor capable of regulating its own transcription. The clinicopathological features and behavior do not differ between pseudomyogenic haemangioendotheliomas with SERPINE1-FOSB and ACTB-FOSB fusions, although tumors with the ACTB variant more often present as solitary lesions.

Macroscopic Appearance

Grossly, margins are ill defined and the cut surface is firm and grey or white. Most tumor nodules are 1–2.5 cm in greatest dimension; only 10% of tumors are > 3 cm in size.

Histopathology

The tumor is composed of sheets and loose fascicles of plump spindle cells with abundant, brightly eosinophilic cytoplasm, sometimes mimicking rhabdomyoblasts. A minor component of cells with epithelioid cytomorphology is often present; but sometimes epithelioid cells predominate. Intraosseous lesions are often dominated by epithelioid cells with marked cytoplasmic eosinophilia, associated with reactive woven bone, hemorrhage, and osteoclast-like giant cells. The tumor cells contain vesicular nuclei with generally small nucleoli. The degree of nuclear atypia is usually mild, and mitotic activity is scarce. About 10% of tumors show notable pleomorphism or large nucleoli. Occasional tumors contain focally myxoid stroma. About 50% of cases contain prominent stromal neutrophils. The tumors show infiltrative margins.

By immunohistochemistry, these tumors show diffuse expression of keratins (with AE1/AE3 but not MNF116) and the endothelial transcription factors FLI1 and ERG. About 50% of cases are positive for CD31. Focal expression of SMA is observed in one third of tumors. Nuclear staining for FOSB is a consistent finding.

Cytology

Not clinically relevant

Prognosis and Prediction

Approximately 60% of patients with this tumor type experience local recurrences (often multiple) or develop additional nodules in the same anatomical region. The interval between excision of the primary tumor and recurrence is usually short, within 1–2 years. The relationship between margin status and recurrence has not been established. Regional lymph node and distant metastases are uncommon (< 5%), most often occurring years or decades after presentation, rarely within a short interval. Metastatic sites may include lungs, bones, and soft tissues. Histological features do not predict metastasis.

Clinical Features

Diagnostic Molecular Pathology

Detection of FOSB rearrangement can be helpful for diagnosis.

Essential and Desirable Diagnostic Criteria

Essential: plump spindle or more rarely epithelioid cell morphology with vesicular chromatin and eosinophilic cytoplasm; fascicular or sheet-like growth pattern; expression of ERG, FOSB, and keratins (AE1/AE3).

Desirable: demonstration of FOSB gene rearrangement (in selected cases).

ribbon

Make a Donation

Help us move closer to a world where people do not die from sarcoma

Make a Donation
ribbon

section